Health Catalyst, Inc.
HCATdata completeness 100%9 fiscal years on fileData notes: no data for concept 'interestExpense'
Health Catalyst, Inc. earns about -16% on invested capital, but has diluted owners by 47% over 5 years — worth asking whether the growth reaches owners. The cash-flow models don't apply cleanly here — the ledger says why below.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.
| Figure | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Revenue | $241.9M1 | $276.2M2 | $295.9M3 | $306.6M3 | $311.1M3 |
| Net income | −$153.2M4 | −$137.4M5 | −$118.1M6 | −$69.5M6 | −$178M6 |
| Operating cash flow | −$23.1M7 | −$35.3M8 | −$33.1M9 | $14.6M9 | $731,0009 |
| Capital expenditure | $10.5M10 | $2.17M11 | $1.24M12 | $1.62M12 | $968,00012 |
| Free cash flow (derived) | −$33.6M7 | −$37.4M8 | −$34.3M9 | $12.9M9 | −$237,0009 |
| Total debt | $180.9M13 | $226.5M14 | $456.1M15 | $764.7M16 | $306.5M16 |
| Cash & equivalents | $193.2M17 | $116.3M18 | $106.3M19 | $249.6M20 | $50.8M20 |
| Diluted shares | 47.5M | 54.1M | 56.4M | 60.2M | 69.9M |
Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).
10 shares is a claim on $35.16 of net worth that earned you −$25.46 and generated −$0.03 of cash last year, against $43.85 of debt.
It earned an average -16% on invested capital over 5 years. Compare that to what it costs to fund the business.
seeing a moat in the numbers →Share count is up 47% over 5 years — owners have been diluted. Worth asking what they got for it. Total debt has risen 69% over the same window.
reading capital allocation →Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.
Different models answer different questions — which to trust when →
- 10-K · period ending 2021-12-31 · accession 0001636422-24-000016 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2022-12-31 · accession 0001636422-25-000028 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2023-12-31 · accession 0001636422-26-000035 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2021-12-31 · accession 0001636422-24-000016 (NetIncomeLoss)
- 10-K · period ending 2022-12-31 · accession 0001636422-25-000028 (NetIncomeLoss)
- 10-K · period ending 2023-12-31 · accession 0001636422-26-000035 (NetIncomeLoss)
- 10-K · period ending 2021-12-31 · accession 0001636422-24-000016 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2022-12-31 · accession 0001636422-25-000028 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2023-12-31 · accession 0001636422-26-000035 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2021-12-31 · accession 0001636422-24-000016 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2022-12-31 · accession 0001636422-25-000028 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2023-12-31 · accession 0001636422-26-000035 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2021-12-31 · accession 0001636422-23-000033 (LongTermDebtNoncurrent)
- 10-K · period ending 2022-12-31 · accession 0001636422-24-000016 (LongTermDebtNoncurrent)
- 10-K · period ending 2023-12-31 · accession 0001636422-25-000028 (LongTermDebtNoncurrent)
- 10-K · period ending 2024-12-31 · accession 0001636422-26-000035 (LongTermDebtNoncurrent)
- 10-K · period ending 2021-12-31 · accession 0001636422-23-000033 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2022-12-31 · accession 0001636422-24-000016 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2023-12-31 · accession 0001636422-25-000028 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2024-12-31 · accession 0001636422-26-000035 (CashAndCashEquivalentsAtCarryingValue)